These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1240 related articles for article (PubMed ID: 34423578)
21. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794 [TBL] [Abstract][Full Text] [Related]
22. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974 [TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. Wang Y; Han H; Zhang F; Lv T; Zhan P; Ye M; Song Y; Liu H Br J Cancer; 2022 Sep; 127(5):948-956. PubMed ID: 35641819 [TBL] [Abstract][Full Text] [Related]
24. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325 [TBL] [Abstract][Full Text] [Related]
25. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185 [TBL] [Abstract][Full Text] [Related]
26. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442 [TBL] [Abstract][Full Text] [Related]
27. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391 [TBL] [Abstract][Full Text] [Related]
28. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552 [TBL] [Abstract][Full Text] [Related]
29. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729 [TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Wang Q; Liu F; Liu L Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952 [TBL] [Abstract][Full Text] [Related]
31. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521 [TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078 [TBL] [Abstract][Full Text] [Related]
33. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy. Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611 [TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
35. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821 [TBL] [Abstract][Full Text] [Related]
36. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Park R; Lopes L; Saeed A Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269 [TBL] [Abstract][Full Text] [Related]
37. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175 [TBL] [Abstract][Full Text] [Related]
38. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens. Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792 [TBL] [Abstract][Full Text] [Related]
39. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757 [TBL] [Abstract][Full Text] [Related]
40. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]